ArticleDiscover oncology2025
Exploring the role of PANoptosis related genes in the prognosis of oral squamous cell carcinoma subtypes based on multi-omics analysis.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Identification and validation of a prognostic signature comprising inflammation and pyroptosis-related genes in oral squamous cell carcinoma.Frontiers in immunology · 2026Article
- Pain-Related PANoptosis Gene Signature Predicts Prognosis and Guides Therapy in Oral Squamous Cell Carcinoma.Technology in cancer research & treatmentArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundOral squamous cell carcinoma (OSCC) has a poor prognosis. PANoptosis, involving apoptosis, pyroptosis, and necroptosis, may be linked to cancer. Identifying OSCC subtypes and creating prognostic models based on PANoptosis-related genes (PRGs) can improve diagnosis and treatment.
methodsRNA-seq and DNA methylation data from OSCC patients in The Cancer Genome Atlas (TCGA) were analyzed. Clustering algorithms identified OSCC subtypes, which were examined for differences in spatial distribution, biological pathways, drug sensitivity, prognosis, and immune infiltration. Prognostic genes were identified using Cox regression analyses. Mendelian randomization identified genes linked to OSCC. Drug sensitivity and tumor mutation load were assessed. Single-cell RNA sequencing (scRNA-seq) data explored the expression of prognostic genes. qRT-PCR verified gene expression.
resultsOSCC subtypes based on PRGs showed differences in prognosis, immunity, drug sensitivity, and pathways. Pantothenate and CoA biosynthesis pathways varied among subtypes, with immune cells highly infiltrated in CS1. The prognostic model highlighted differences in prognosis and immunotherapy response. BAK1 was causally linked to OSCC risk. Combining TMB score improved patient stratification. qRT-PCR confirmed differences in gene expression between control and OSCC groups. Monocytes were identified as high-scoring cells, with TGFb and MIF pathways important in cell communication.
conclusionTwo OSCC subtypes and eight prognostic genes (TGFBR3, CYCS, HDAC9, PLK1, GSDMB, HSPA4, BAK1, SOD2) were identified, aiding in treatment and risk stratification. BAK1 is causally linked to OSCC risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.